Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDental/Oral & MaxillofacialAetna TMJ/TMD Coverage & Prior Auth Policy | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0028

    Temporomandibular Disorders (TMD/TMJ) Management

    Customize your policy alerts

    Sign up for Aetna Policy 0028 alerts

    Get alerted when Policy 0028 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs diagnostic, non-surgical, and surgical management of temporomandibular disorders for Aetna medical plans, including documentation and review requirements for TMJ surgery and coverage stance on various therapies.

    Policy Summary
    PayerAetna
    PolicyTemporomandibular Disorders (TMD/TMJ) Management
    Policy CodePolicy 0028
    Change TypeNo material change
    Effective Date08/01/1995
    Last ReviewMar 12, 2026
    Next Review Date01/14/2027
    Key ActionSubmit the Aetna Temporomandibular Disorder Questionnaire, physical exam, imaging reports, and documentation of 3–6 months of non-surgical management when requesting TMJ surgical review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3-6 moRequired non-surgical management prior to surgical review
    1Oral splint considered medically necessary
    ~200+Listed procedure/coding entries
    low-to-very-lowOverall evidence quality (selected interventions)
    03/12/2026Last review date

    Coverage Criteria and Medical Necessity

    Surgical Medical Necessity Criteria

    TMJ surgery and specific procedures are considered medically necessary when ALL general criteria are met and the procedure-specific criteria are satisfied:

    General surgical criteria: 1) Severe pain or functional disability produced by an intra-capsular condition; AND 2) The intracapsular condition is confirmed by MRI, CT, or other imaging; AND 3) The condition has not responded to nonsurgical management and surgery is the only remaining option (nonsurgical management should include three or more months where appropriate of professional physical therapy, pharmacological therapy, behavioral therapy, manipulation, and reversible intra-oral appliances).3 months typically

    Exceptions for immediate surgical intervention (e.g., bony ankylosis, failed TMJ prosthetic implants).

    Arthrocentesis indications: Arthrocentesis with insufflation, lysis, and lavage is medically necessary when imaging and clinical exam reveal anchored disc phenomenon, anterior disc displacement without reduction and without effusion, osteoarthritis without fibrosis or loose bone particles, open lock, or hemarthrosis.

    Definition of arthrocentesis provided.

    Policy Summary
    PayerAetna
    PolicyTemporomandibular Disorders (TMD/TMJ) Management
    Policy CodePolicy 0028
    Change TypeNo material change
    Effective Date08/01/1995
    Last ReviewMar 12, 2026
    Next Review Date01/14/2027
    Key ActionSubmit the Aetna Temporomandibular Disorder Questionnaire, physical exam, imaging reports, and documentation of 3–6 months of non-surgical management when requesting TMJ surgical review.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityBilling, Codes, and DiagnosisProvider Requirements, Prior Authorization, and DocumentationBackground and Evidence SummariesDefinitions and Key TermsRevision History and Administrative Dates
    Therapeutic arthroscopy indications: Therapeutic arthroscopy is medically necessary when MRI or other imaging confirms adhesions, fibrosis, degenerative joint disease, or internal disc derangement requiring internal modification.
    Open surgical procedure indications: Open procedures (disc repositioning/plication, repair, removal with/without replacement) are medically necessary for congenital anomalies, trauma, or disease in patients who have failed nonsurgical management.
    Arthroplasty/arthrotomy indications: Arthroplasty/arthrotomy is medically necessary when imaging confirms osteoarthritis/osteoarthrosis OR severe disc displacement with degenerative changes or perforation OR severe scarring from prior injury/procedure.
    Joint replacement indications: Joint replacement with an FDA-approved prosthesis is medically necessary as a salvage device for end-stage TMJ disease after unsuccessful conservative and other surgical treatment when imaging documents loss of smooth fossa, damaged non-ball-shaped condyles, persistent inflammatory arthritis unresponsive to other modalities, recurrent fibrous/bony ankylosis, loss of condylar height/occlusal relationship, or failed autologous/alloplastic reconstruction.

    Examples of approved prostheses listed.

    Autogenous grafts may be medically necessary upon individual case review; costochondral grafts considered medically necessary when general joint replacement criteria are met, or for congenital absence/deformity, or post tumor resection reconstruction.

    Non-surgical Management

    Medically necessary non-surgical management — comprehensive conservative care includes ALL of the following unless contraindicated:

    Comprehensive non-surgical care: Professional physical therapy; pharmacological therapy (NSAIDs, non-opiate analgesics, low‑dose tricyclics, adjuvant agents; opiates/corticosteroids/anxiolytics/muscle relaxants for refractory pain); behavioral therapies (relaxation, biofeedback, cognitive behavioral therapy); manipulation when indicated; reversible intra-oral appliances when clinically indicated.

    Appliances for bruxism typically excluded under medical plans; only one oral splint considered medically necessary for TMD/TMJ therapy; prolonged use >6 months not routinely necessary without individual review.

    Policy sections (headers only)

    Policy contains these titled sections that define coverage and medical necessity:

    Policy Sections: Medical Necessity; Diagnostic Testing; Acupuncture and Trigger Point Injections; Manipulation for reduction of fracture or dislocation of the TMJ; Intra‑Articular Corticosteroid Injection; General medical necessity criteria for TMJ surgery; Surgical procedure‑specific criteria; Surgical Procedures; Policy Limitations and Exclusions; Experimental, Investigational, or Unproven (diagnostic, non‑surgical, surgical treatments)

    Section headers only in this excerpt; detailed criteria appear elsewhere in the policy.

    Surgical intervention criteria

    Covered when ALL of the following are met

    Conservative therapy tried: Non‑surgical conservative therapies (occlusal appliance therapy, physical therapy, medical management, relaxation/CBT) have been tried and documented prior to surgical intervention.documented trial (typically ≥3 months)

    NIH and specialty guidance emphasize conservative and reversible therapy first

    Surgical indication severity: Pain and/or dysfunction are moderate to severe or refractory despite conservative care.clinical judgment and documentation

    Surgical intervention indicated only when nonsurgical therapy ineffective

    Imaging and diagnostic criteria

    Covered when ALL of the following are met

    Imaging for surgery planning: Specialized radiological studies (including CT or MRI) and ultrasonography are appropriate and considered medically necessary when used in conjunction with anticipated surgical management or to assess internal derangement in patients with closed lock/limited opening.clinical indication for surgery or limited opening

    MRI is useful for disc morphology assessment though diagnostic efficacy evidence is limited; additional X‑rays beyond a panoramic view are typically reserved for surgical planning.

    Alloplastic joint prosthesis

    Policy considerations / coverage stance

    Partial TMJ prosthesis had limited pre‑approval data and historically was not approved by the FDA for partial devices; safety and effectiveness data are limited and case‑by‑case review is required.case‑by‑case evidence and documentation

    Partial prosthesis safety/effectiveness questioned

    Total TMJ prosthesis: Total TMJ prostheses (for example, W. Lorenz, Christensen, TMJ Concepts) have FDA approval for defined indications and may be medically necessary as salvage devices for end‑stage TMJ disease when conservative and other surgical treatments have failed; documentation of device‑specific indications and prior treatments is required.FDA‑approved indications and prior conservative therapy

    Device‑specific outcomes and follow‑up completeness vary; certain older devices (eg, Vitek‑Kent, silastic implants) are not considered medically necessary.

    Evidence-based coverage considerations (background)

    Evidence summaries and implied coverage considerations

    Arthrocentesis alone has been shown in multiple studies and reviews to reduce pain and improve jaw function in TMJ osteoarthritis; additional intra‑articular supplements have not consistently improved final outcomes.

    Derwich et al (2021) concluded adjunctive injections did not improve final outcomes and CS may have negative effects on cartilage.

    Adjunct intra‑articular supplements: Evidence for intra‑articular supplements (HA, PRP/PRGF, corticosteroids) is heterogeneous and inconsistent: HA shows benefit versus saline but similar outcomes to corticosteroids or oral appliances; PRP/PRGF show small or transient advantages in some trials but no consistent durable benefit.

    Systematic reviews rate evidence quality as low and heterogeneous, limiting firm conclusions and supporting cautious use and documentation when requested.

    Botulinum toxin (BTX‑A): Randomized trials and systematic reviews report inconsistent and generally low‑quality evidence for BTX‑A in myofascial TMD; routine use is not supported by high‑quality evidence.

    Evidence insufficient to recommend widespread use; consider individual case documentation.

    Intra‑articular biologics for JIA/TMJ arthritis: Retrospective and small studies of IA biologics (eg, infliximab) in refractory juvenile idiopathic arthritis indicate limited effectiveness in preventing progression; evidence is insufficient to support routine use.

    Clinical justification and prior therapy documentation advised for such interventions.

    Evidence summaries and coverage considerations

    Key evidence-based conclusions and considerations from cited systematic reviews and trials

    Manual therapy evidence: Systematic review (Vieira et al 2023) found moderate‑to‑high quality evidence of small additional effects of manual therapy on pain intensity, maximum mouth opening, and disability; effect sizes were modest and may not be clinically important.

    Supports inclusion of manual therapy as part of conservative care but benefits modest and require documentation of response.

    Combination therapy vs therapy without splint: Kelemen et al (2024) found marginal differences between combination therapy (splint plus physiotherapy/manual therapy/counseling) and those therapies alone, concluding no clear additive superiority of combination therapy.

    Both approaches may be used; document rationale if selecting combination therapy.

    Intra‑articular biologics (PRP/PRF/HA): Network meta‑analysis (Xu et al 2023) of 12 RCTs (421 patients) demonstrated improvement with IA treatments versus placebo; PRF showed favorable short‑term analgesic effects and PRP had some advantage at 6 months, but heterogeneity in preparations and dosing limits definitive conclusions.

    Comparative effectiveness remains uncertain; additional high‑quality trials needed.

    Telemedicine: Systematic review (Abdul et al 2023) identified limited evidence (2 studies) suggesting telemedicine may be promising for some TMD care but lacks robust data and physical exam components, limiting use in complex cases.

    Telemedicine may be appropriate for select patients but not replace in‑person exam when complexity warrants.

    BMAC for TMJ OA: Small pilot trial (Fayed et al 2024) comparing BMAC to HA after arthrocentesis (24 patients) showed trends toward long‑term joint repair with BMAC at 12–18 months; findings are preliminary and considered investigational pending larger confirmatory studies.

    Recommend prior authorization and robust supporting evidence for use outside trials.

    The policy lists multiple therapies and diagnostic technologies that Aetna considers experimental, investigational, or unproven for TMD/TMJ because of insufficient or low‑quality evidence. Examples include: artificial intelligence diagnostic algorithms; cephalometric or lateral skull x‑rays; computerized mandibular scan/kinesiography/jaw tracking; diagnostic study models; electromyography (EMG) / surface EMG; electronic registration devices (Myomonitor); genetic testing; joint vibration analysis; salivary stress biomarkers and circulating omentin‑1 measurements; thermography; autologous blood injections (including plasma rich in growth factors/PRGF and platelet‑rich plasma/PRP); bio‑oxidative ozone therapy; magnetic neurostimulator devices; MIRO therapy; gallium aluminum arsenide (GaAlAs) laser / photobiomodulation; cryo‑analgesia; intra‑articular injections of hyaluronic acid, bone marrow aspirate concentrate (BMAC), rituximab, or other biologics; stem cell therapies; and numerous other listed modalities (see policy for full enumeration).

    The policy notes that some small preliminary trials report positive signals for certain modalities (for example, limited small trials of ozone therapy or magnetic stimulation), but emphasizes these findings are preliminary and require validation in well‑designed, larger studies before the treatments can be considered established.

    Reversible intra‑oral appliances (occlusal splints) may be considered medically necessary for selected TMD/TMJ patients when there is documented clinically significant masticatory impairment with pain and/or loss of function. Only one oral splint or appliance is considered medically necessary for TMD/TMJ therapy. Appliances specifically for bruxism are typically excluded under Aetna medical plans and may be covered under dental plans; check benefit plan descriptions. Prolonged use greater than 6 months is not considered routinely medically necessary unless individual case documentation justifies continued use. Replacement of lost or stolen appliances is not covered; repairs or other replacements are subject to review.

    The policy identifies specific CPT/HCPCS and dental codes that are either not covered for the indications listed or are subject to coverage conditions. Notable examples include 0232T (PRP injection) and 0481T (autologous white blood cell concentrate) as codes called out for non‑covered indications in the bulletin; other codes (e.g., certain 2056x trigger‑point codes, 20560/20561) and numerous surgical/reconstructive CPT ranges and dental procedure codes are likewise listed as not covered for TMD indications in this policy excerpt. See the coding section for the complete code lists and specific coverage status.

    The policy states that certain total joint prostheses removed from the market (for example, the Vitek‑Kent total joint prosthesis) and silastic implants are not considered medically necessary due to historical problems with biocompatibility, fragmentation, wear, and foreign‑body reactions. By contrast, FDA‑approved systems such as the W. Lorenz total TMJ replacement have specific approved indications and supporting case‑series data, and are considered under the policy when prosthesis‑specific criteria and prior treatment documentation are met.

    The policy characterizes irreversible mandibular repositioning procedures — including equilibration, orthodontics aimed at occlusal change, full‑mouth reconstruction, and orthognathic surgery — as generally indefensible as medically necessary for most TMDs. Authors cited argue biologic homeostasis of the stomatognathic system supports conservative care and therefore irreversible repositioning procedures are at risk for denial unless strong, case‑specific medical justification is provided.

    The policy does not support routine coverage of intra‑articular biologics or adjuncts (for example, PRGF/PRP, hyaluronic acid, or other intra‑articular biologic agents) for TMD/TMJ without robust clinical justification. Systematic reviews and RCTs cited show heterogeneous and inconsistent results: arthrocentesis alone often improves pain and function and additional intra‑articular supplements have not consistently produced durable added benefit (one RCT of PRGF showed no added improvement at 2 years), and overall evidence quality is low or inconsistent for routine adoption.

    Background excerpts in the policy do not assert any single blanket coverage exclusion beyond the enumerated experimental/unproven therapies and code‑level restrictions; clinical applicability and plan benefit language determine final coverage scope. The document therefore contains no separate explicit universal exclusion statement in the background snippets provided.

    Evidence for cryo‑analgesia in TMJ pain is very limited and derives mainly from small retrospective series; the policy notes a 17‑patient retrospective report with mixed duration of relief and that major clinical overviews (e.g., UpToDate) do not list cryo‑analgesia as a standard management option. Thus cryo‑analgesia is not established as standard care for TMD.

    Telemedicine may be useful for certain TMD assessments, but the policy cautions that remote evaluation lacks direct physical examination of jaw range of motion and muscle strength. Therefore telemedicine may be unsuitable for severe or complex TMD cases that require comprehensive in‑person examination and imaging to establish surgical or invasive treatment indications.

    Procedures such as disc plication, orthognathic surgery, and other permanent mandibular repositioning approaches are described with coverage caveats: disc plication outside specified indications and permanent mandibular repositioning (e.g., full‑mouth reconstruction, orthognathic surgery) are listed among interventions that are generally not medically necessary for typical TMD presentations, and therefore require strong, documented justification when requested.

    Multiple technologies and procedures are explicitly categorized as experimental or unproven due to preliminary or limited data. Examples called out include bio‑oxidative ozone therapy, magnetic neurostimulator devices, MIRO therapy, and other novel modalities; the policy emphasizes that available studies are small and preliminary and that effectiveness has not been established.

    The policy states that specialized radiological studies (for example, cephalometric x‑rays, tomograms, submental vertex views) are not medically necessary for routine evaluation of TMD unless surgery is being considered; advanced imaging is appropriate when it will affect surgical planning or management.

    The policy reports that low‑level laser therapy (LLLT), peripheral or intra‑articular ketamine injections, and certain local NMDA‑targeted injections have not demonstrated reliable clinical benefit in controlled trials. LLLT randomized trials cited showed no significant advantage over placebo in several studies, and intra‑articular or peripheral ketamine did not demonstrate clinically meaningful effects, leading the policy to not support these as established treatments.

    Electromyography (EMG) and joint vibration analysis (JVA) lack sufficient diagnostic accuracy for TMD. Systematic reviews cited in the policy found poor sensitivity, inconsistent specificity, and methodological limitations, concluding there is no evidence to support routine use of EMG or JVA as reliable diagnostic tests for TMD.

    The policy highlights treatments with insufficient or low‑quality evidence of durable benefit. Examples include PRGF/PRP where randomized data show inconsistent or transient improvements (one RCT found no added benefit at 2 years), and botulinum toxin A (BTX‑A) where systematic reviews report small short‑term effects but overall low‑quality, inconsistent evidence insufficient to support routine use. Intra‑articular biologic agents such as infliximab in refractory JIA TMJ disease showed progression in many patients in retrospective series.

    MIRO therapy is noted in the policy as having a lack of evidence regarding its effectiveness for TMD/TMJ dysfunctions; available descriptions are informational and the policy states that evidence is insufficient to support its routine use.

    Bio‑oxidative ozone therapy and magnetic neurostimulator treatments are supported only by small preliminary studies; the policy views their effectiveness as not established and calls for validation in well‑designed trials before coverage as standard care.

    Low‑level GaAlAs laser therapy (a form of photobiomodulation) has mixed and generally insufficient evidence: meta‑analyses and randomized trials report variable results depending on device parameters and dosing, and the policy concludes current evidence is inadequate to draw strong conclusions about benefits for masticatory muscle pain or maximal mouth opening.

    Artificial intelligence diagnostic algorithms for TMD have been studied in small retrospective and case‑control series; a systematic review found pooled accuracy but rated the certainty of evidence as very low because of heterogeneity and high risk of bias, and the policy does not regard AI algorithms as established standalone diagnostic tools.

    Procedures with only preliminary evidence — for example, intra‑articular bone marrow aspirate concentrate (BMAC) injections for TMJ osteoarthritis — are considered investigational. A small pilot trial (24 patients) reported trends toward joint repair at 12–18 months versus HA, but the policy emphasizes these findings are preliminary and larger confirmatory trials with longer follow‑up are required before widespread adoption.

    Billing, Codes, and Diagnosis

    Covered CPT Codes (partial list shown in chunk 29)CPTCovered
    20552Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s).
    20553Injection(s); single or multiple trigger point(s), 3 or more muscles.
    20605Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; without ultrasound guidance [not covered for viscosupplementation injection] [not covered for intra-articular injections of rituximab] [not covered for Intra-articular injection of analgesic].
    20611Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance, with permanent recording and reporting.
    20910Cartilage graft; costochondral [autologous].
    21010Arthrotomy, tempomandibular joint.
    21050Condylectomy, tempomandibular joint (separate procedure).
    21060Meniscectomy, partial or complete, tempomandibular joint (separate procedure).
    21070Coronoidectomy (separate procedure).
    21073Manipulation of temporomandibular joint(s) (TMJ), therapeutic, requiring an anesthesia service (ie, general or monitored anesthesia care).
    1–10 of 16
    1/2
    Covered CPT Codes (additional surgical/arthroscopy codes)CPTCovered
    21193Reconstruction of mandibular rami, horizontal, vertical, C, or L osteotomy; without bone graft.
    21198Osteotomy, mandible, segmental.
    21240Arthroplasty, temporomandibular joint, with or without autograft (includes obtaining graft).
    21242Arthroplasty, temporomandibular joint, with allograft.
    21243Arthroplasty, temporomandibular joint, with prosthetic joint replacement.
    21255Reconstruction of zygomatic arch and glenoid fossa with bone and cartilage (includes obtaining autografts).
    21440Closed treatment of mandibular or maxillary alveolar ridge fracture (separate procedure).
    21445Open treatment of mandibular or maxillary alveolar ridge fracture (separate procedure).
    21450Closed treatment of mandibular fracture; without manipulation.
    21451Closed treatment of mandibular fracture; with manipulation.
    1–10 of 23
    1/3
    Mixed CPT/HCPCS/Dental codes (therapies, imaging, devices)mixedCovered
    70355Orthopantogram (eg, panoramic x-ray).
    76536Ultrasound, soft tissues of head and neck; real time with image documentation [ultrasonography of temporomandibular joints].
    90832-90840Psychotherapy codes.
    90901Biofeedback training by any modality.
    97010Application of a modality; hot or cold packs.
    97110Therapeutic procedure; therapeutic exercises.
    97810-97814Acupuncture codes (initial and additional 15-minute units, with/without electrical stimulation).
    J0585Botulinum toxin type A, per unit.
    E0720Transcutaneous electrical nerve stimulation (TENS) device, 2 lead.
    D0330Panoramic radiographic image.
    1–10 of 11
    1/2
    Codes subject to coverage conditions or listed as not covered for certain indicationsmixed
    0232TInjection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
    0481TInjection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed.
    20560Needle insertion(s) without injection(s); 1 or 2 muscle(s).
    20561Needle insertion(s) without injection(s); 3 or more muscles.
    70328Radiologic examination, temporomandibular joint, open and closed mouth; unilateral [covered only when used in conjunction with anticipated surgical management].
    70486Computerized tomography, maxillofacial area; without contrast material [covered only when used in conjunction with anticipated surgical management].
    HCPCS/Dental codes not covered or restrictedmixedNot Covered
    A4556Electrodes (e.g., apnea monitor), per pair. (listed as HCPCS not covered for indications in CPB)
    A4595Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES). (listed as HCPCS not covered for indications in CPB)
    D5110-D5899Prosthodontics (removable) — ranges listed as not covered for indications in CPB.
    D7899Unspecified TMD therapy, by report. (listed)
    Listed CPT/HCPCS/Dental codesmixed
    D07022-D cephalometric radiographic image – image capture only.
    D5931Obturator prostheses.
    D5933Obturator prostheses.
    D5936Obturator prostheses.
    D5934Mandibular resection prosthesis with guide flange.
    D5982Surgical stent.
    D5988Surgical splint.
    D7630Mandible, open reduction (teeth immobilized, if present).
    D7640Mandible, closed reduction (teeth immobilized, if present).
    D7730Mandible, open reduction.
    1–10 of 34
    1/4
    Other HCPCS injectable codes listedHCPCS
    J0702Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg.
    J1100Injection, dexamethasone sodium phosphate, 1 mg.
    J1700Injection, hydrocortisone acetate, up to 25 mg.
    J1720Injection, hydrocortisone sodium succinate, up to 100 mg.
    J2650Injection, prednisolone acetate, up to 1 ml.
    J3300Injection, triamcinolone acetonide, preservative free, 1 mg.
    ICD-10 diagnosis codes (selection criteria required)ICD-10
    M26.601 - M26.69Temporomandibular joint disorders.
    S02.400A - S02.413S S02.42xA - S02.42xS S02.600A - S02.69xSFracture of mandible, closed or open, or malar and maxillary bones closed or open.
    S03.00xA - S03.02xSDislocation of jaw (closed or open).
    inv-37: Arthrocentesis ultrasound guidance requirement
    Key coding noteCPT 20611 denotes arthrocentesis/aspiration/injection with ultrasound guidance and requires permanent recording and reporting.
    Related CPT (no-US)CPT 20605 describes arthrocentesis/aspiration/injection of an intermediate joint (eg, temporomandibular) without ultrasound guidance and has specific not-covered indications (eg, viscosupplementation, rituximab, analgesic IA injection).
    Implication for documentationWhen billing for image-guided TMJ procedures, include documentation of ultrasound guidance and permanent recording when using 20611 to support code selection.
    inv-38: Clinical follow-up completion in studies
    Common long-term follow-up timepoint36 months is reported as a timepoint for outcome data (eg, pain reduction and functional measures) in post-approval joint prosthesis studies.
    Example outcome at 36 monthsPartial and total joint prosthesis studies reported a mean 4.9-cm reduction in pain on a 10-cm VAS at 36 months (manufacturer post-approval data).
    Note on data completenessFollow-up completeness at 36 months was limited (eg, 44–54% of subjects had available outcome data), which should be considered when interpreting long-term results.

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    TMJ surgery precertification review required

    All TMJ surgical precertification requests or claims are reviewed by Aetna's Oral and Maxillofacial Surgery (OMS) Patient Management Unit; submit a problem-specific history (Aetna TMJ Questionnaire), physical exam, TMJ imaging reports, records documenting 3–6 months of non-surgical management (nature, results, and findings), and the proposed treatment plan for review.

    • Include Aetna Temporomandibular Disorder Questionnaire and problem-specific history
    • Provide TMJ radiographs/diagnostic imaging reports and physical examination findings
    • Document 3–6 months of non-surgical management with results and the proposed surgical plan
    Billing Rule

    Imaging covered only if tied to anticipated surgery

    Certain imaging studies (e.g., CT, MRI, specified TMJ radiographs) are considered medically necessary only when used in conjunction with anticipated surgical management; when submitting imaging, link the study to planned surgery or surgical evaluation.

    • CT or MRI: only when used in conjunction with anticipated surgical management
    • Specific codes (e.g., 70328, 70486, 70487, 70488) are covered only with anticipated surgical management
    Prior Authorization

    Prior authorization for total TMJ replacement — document indication and prior treatments

    Requests for total TMJ replacement must document FDA‑approved indication and prior unsuccessful conservative and surgical treatments; provide imaging demonstrating the device‑level criteria (e.g., loss of smooth fossa, damaged condyles, recurrent ankylosis) and prior treatment history.

    • Document prior conservative management and other surgical attempts
    • Include imaging showing one or more device indication findings (e.g., non–ball-shaped condyles, loss of articular fossa)
    Denial Risk

    Irreversible mandibular repositioning — strong justification required

    Irreversible mandibular repositioning procedures (equilibration, orthodontics, full‑mouth reconstruction, orthognathic surgery) are generally not considered medically necessary for most TMDs and will require strong, case-specific justification if prior authorization is sought.

    • Provide clear documentation of conservative‑treatment failure and specific medical necessity if requesting authorization
    • Anticipate high risk for denial when irreversible repositioning is proposed without robust justification
    Prior Authorization

    PA recommended for intra‑articular biologics and adjuncts (PRGF/PRP/HA)

    Prior authorization is recommended for intra‑articular biologic or adjunctive injections (PRGF/PRP, hyaluronic acid, other intra‑articular biologics) because evidence is inconsistent; include prior conservative care and rationale when requesting coverage.

    • Include prior conservative treatment attempts and results
    • Provide trial-level evidence or rationale supporting off‑label/adjunctive IA biologic use
    Note

    No explicit prior authorization code requirements in this section

    This background section summarizes diagnostic and procedural evidence (ultrasound guidance, CT confirmation, imaging sensitivity/specificity) but does not specify explicit prior authorization code requirements or instructions.

    • Use the documented imaging and technique evidence to support clinical submissions, but do not expect code‑level PA rules here
    Documentation Required

    Document imaging guidance and confirmation for image‑guided TMJ injections/surgery

    When planning image‑guided intra‑articular injections or TMJ surgery, document the imaging guidance modality (e.g., ultrasound), CT confirmation if used, laterality/number of injections, and accuracy of needle placement to support the procedure.

    • Record imaging guidance modality (US, CT) and whether CT confirmation was performed
    • Document needle placement accuracy (CT‑confirmed intra‑articular placement rates) and sterile technique
    Prior Authorization

    PA recommended for experimental biologic IA injections (e.g., BMAC)

    Emerging intra‑articular biologic procedures (for example, BMAC for TMJ osteoarthritis) are preliminary; obtain prior authorization and submit supporting trial data, rationale, and outcomes when requesting coverage.

    • Provide the small‑trial data, follow‑up intervals, and justification for use in the individual patient
    • Anticipate investigational review and potential denial without strong supporting evidence
    Note

    No specific prior authorization code instructions in this portion

    This portion of the policy provides background evidence and does not list specific prior authorization codes, numeric PA rules, or code‑level submission instructions.

    • Refer to other sections for code lists and PA procedures; no new code requirements are stated here
    Step Therapy

    Surgery only after failure of comprehensive non‑surgical management (≥3 months)

    Surgery is considered only after documented failure of comprehensive non‑surgical management — include documentation of at least 3 months (typically 3–6 months) of professional physical therapy, pharmacologic therapy, behavioral therapy, manipulation (if indicated), and reversible intra‑oral appliances where appropriate.

    • Document nature and results of non‑surgical treatments over 3–6 months
    • Confirm that surgery is being considered only after these measures have been exhausted except in urgent cases (e.g., bony ankylosis)
    Documentation Required

    Document conservative therapies and trials before surgery

    Non‑surgical conservative therapies (occlusal appliance therapy, physical therapy, medical management, behavioral therapy) should be tried and documented prior to consideration of surgical interventions.

    • Document occlusal appliance use, physical therapy courses, medications, and behavioral therapy sessions and outcomes
    • Appliance therapy trials for intracapsular problems should be provided for at least 2–3 months when tolerated
    Documentation Required

    Conservative‑first approach — document manual therapy and therapeutic exercise

    Conservative, low‑cost, reversible therapies such as manual therapy, therapeutic exercise, and related non‑invasive modalities are primary management options and should be documented as tried prior to invasive or irreversible procedures.

    • Record dates, frequency, and response to manual therapy, therapeutic exercise, and counseling
    • Include objective outcome measures (pain VAS, MMO/MMI) when available
    Step Therapy

    Consider arthrocentesis as first invasive step; document response before adjuncts

    Given consistent evidence that arthrocentesis alone reduces pain and improves jaw function and that adjunctive intra‑articular supplements have not consistently improved outcomes, clinicians should consider arthrocentesis before adding intra‑articular supplements and document the rationale.

    • Document indication for arthrocentesis and clinical response before pursuing adjunctive IA injections
    • If adjunctive IA agents are used, include justification and prior arthrocentesis outcomes
    Note

    No formal step‑therapy rules specified

    No formal step‑therapy program is prescribed in the policy; evidence summaries note arthrocentesis alone often provided benefit and that adjunctive IA supplements did not consistently add durable improvement.

    • Although no mandated step‑therapy algorithm exists, document prior treatments and responses when requesting advanced therapies
    • Use evidence summaries to support clinical decision‑making rather than relying on a formal step protocol
    Documentation Required

    Document trials of conservative therapy before invasive procedures

    Evidence supports conservative first‑line treatments (NSAIDs, non‑biologic DMARDs where applicable, counseling, manual/physical therapy, splints) prior to more invasive procedures; document trials, duration, and outcomes.

    • Record medication trials (agents, doses, duration) and response
    • Include objective outcome measures and timeframes (e.g., 1, 3, 6 months) when available
    Documentation Required

    Conservative combination therapies should be documented prior to escalation

    Combination conservative therapies (counseling, manual therapy, physical therapy, splint therapy) have small effect sizes but are supported as initial care; document use of combination approaches before escalating to invasive or experimental treatments.

    • Provide records of combined conservative modalities and objective measures of improvement or lack thereof
    • Note duration and adherence to combination therapy when included in surgical review
    Note

    No step‑therapy mandates in these excerpts — still document prior care

    There are no formal step‑therapy mandates in the cited sections; however, document prior non‑surgical care and responses when submitting requests for advanced or experimental treatments.

    • Include clear chronology of prior therapies and objective outcomes when seeking authorization for non‑standard procedures
    Documentation Required

    Submit Aetna TMJ Questionnaire, exam, imaging, and 3–6 months non‑surgical therapy documentation

    Submit the Aetna Temporomandibular Disorder Questionnaire, a focused physical exam, TMJ imaging reports, and records documenting 3–6 months of non‑surgical therapy (nature, results, and findings) along with the proposed treatment plan for surgical reviews.

    • Attach completed Aetna TMJ Questionnaire and problem‑specific history
    • Provide detailed documentation of non‑surgical therapy trials, including dates, providers, interventions, and outcomes
    Billing Rule

    Imaging codes covered only with anticipated surgical management — document linkage

    Certain imaging CPT codes (e.g., 70328, 70330, 70336, 70355, 70486, 70487, 70488, 70540–70543) are covered only when performed in conjunction with anticipated surgical management; when billing these codes, include documentation linking the imaging to planned surgery.

    • When submitting claims for these imaging codes, include the surgical plan or indication for operative management
    • If imaging is for initial evaluation without surgical intent, these codes may not be considered medically necessary
    Billing Rule

    Use and document appropriate procedure/HCPCS/CPT/Dental and ICD‑10 codes

    Bill using the appropriate procedure and HCPCS/CPT/dental codes listed in the policy and include relevant ICD‑10 diagnosis codes (e.g., M26.601–M26.69) when selection criteria are met; ensure coding matches documented indication and imaging.

    • Use covered CPT/HCPCS/D codes from the policy when submission aligns with medical necessity criteria
    • Include ICD‑10 diagnosis codes for TMJ disorders when selection criteria are satisfied
    Documentation Required

    Documentation expectations for orthodontic TMD interventions — ≥2 baseline signs/symptoms

    Orthodontic TMD intervention studies require clear diagnostic criteria and documentation of at least two signs or symptoms of TMD at baseline; when submitting orthodontic interventions for TMD, include baseline signs/symptoms and trial details.

    • Document at least two baseline TMD signs/symptoms and exclude splint‑only or prior surgical cases if applicable
    • Include study‑like criteria if relying on orthodontic intervention evidence
    Documentation Required

    Suggested documentation for IA biologic/adjunct requests (include prior operative details and outcomes)

    When requesting intra‑articular biologic or adjunctive injections (PRGF/PRP/HA/other biologics), include prior operative details (arthroscopy/arthrocentesis), randomized trial‑level justification if available, baseline pain and mandibular opening measurements, imaging findings, prior conservative therapy attempts, and rationale for off‑label or adjunctive use.

    • Provide prior operative reports (arthroscopy/arthrocentesis) and outcomes
    • Include baseline and follow-up outcome measures (pain VAS, MMO/MMI) and relevant trial evidence
    Documentation Required

    Document imaging guidance modality and CT confirmation for image‑guided injections

    Document the imaging guidance modality (e.g., ultrasound) and any CT confirmation used for image‑guided TMJ injections, and specify laterality and number of injections to support accuracy and appropriateness.

    • Record use of US guidance and whether CT confirmation was performed
    • Indicate laterality, number of injections, agent and dose when applicable
    Documentation Required

    Required procedural and outcomes documentation for IA TMJ injections

    For intra‑articular TMJ injections, record the indication (e.g., JIA with MRI evidence of TMJ inflammation), imaging guidance used (US, CT), agent and dose (e.g., triamcinolone hexacetonide/acetonide), and pre/post outcome measures (pain, maximal incisal opening, MRI findings); lack of these procedural and outcomes data may risk denial.

    • Include agent name and dose, imaging guidance, and objective pre/post measures (pain VAS, MIO/MMO)
    • Attach MRI findings when used to justify indication (e.g., JIA inflammation)
    Documentation Required

    Document trial design and outcomes when relying on evidence for biologics or BMAC

    When relying on clinical evidence to justify manual therapy, IA biologics (PRP/PRF), or BMAC, document trial design, outcomes, follow‑up intervals (e.g., 1, 3, 6, 12, 18 months), and specific outcome measures (pain VAS, MMO) from cited RCTs or studies to support medical necessity.

    • Provide cited trial details (design, sample size, follow‑up) and link trial outcomes to the patient’s clinical course
    • Include objective measures and timepoints used in the supporting studies
    Note

    Administrative/contact info — no new clinical documentation requirements

    Administrative and contact information is provided in this policy; this section does not add additional clinical documentation requirements beyond those specified elsewhere in the bulletin.

    • Use the contact and administrative references in the policy for submission queries
    • Follow the documentation lists in the surgical and procedural sections for clinical requirements
    Prior Authorization

    Provide complete problem‑specific documentation for OMS surgical review

    Requests for TMJ surgery undergo OMS patient management unit review and must include problem‑specific history, exam, imaging, documentation of 3–6 months of non‑surgical management, and the proposed surgical plan; failure to provide these items may delay or result in denial.

    • Attach Aetna TMJ Questionnaire and detailed non‑surgical treatment chronology
    • Provide imaging and explicit surgical rationale tied to failed conservative care
    Billing Rule

    Some CPT codes not covered for specified indications — check policy lists

    Certain CPT codes are listed as not covered for specified indications in the policy (for example, arthrocentesis for viscosupplementation injection and some intra‑articular injection indications); follow the policy code exclusions to avoid claim denials.

    • Do not bill covered benefits for indications explicitly listed as not covered (e.g., viscosupplementation via arthrocentesis)
    • Review the policy’s CPT/HCPCS lists before submission
    Billing Rule

    Certain CPT/HCPCS/Dental codes are not covered for listed indications

    Specific CPT/HCPCS/dental codes (e.g., 0232T, 0481T and multiple dental/prosthodontic codes) are identified as not covered for indications listed in the CPB; do not submit claims for these codes for excluded indications.

    • Verify that the billed code is not among those listed as not covered for the requested indication
    • If using an investigational/experimental procedure, expect prior authorization denial without compelling supporting evidence
    Billing Rule

    Specialized radiology not necessary unless surgery planned — document surgical intent

    Specialized radiological studies (e.g., cephalometric x‑rays, tomograms) are not medically necessary for evaluating TMD unless surgery is being considered; if performed for surgical planning, document the surgical intent.

    • When ordering specialized radiology, include statement linking imaging to anticipated surgery
    • Routine use of these studies for non‑surgical evaluation may not be supported
    Denial Risk

    High denial risk for irreversible mandibular repositioning procedures

    Irreversible mandibular repositioning procedures are argued not medically necessary for most TMDs and are at high risk for denial when not supported by documented conservative‑treatment failure and compelling medical necessity.

    • Provide exhaustive prior conservative treatment documentation if requesting authorization
    • Anticipate denials if the procedure is irreversible and lacks strong, case‑specific justification
    Denial Risk

    Potential denial triggers when evidence of durable benefit is limited

    Interventions lacking clear or durable benefit in cited studies (for example, PRGF showing no added improvement at 2 years; inconsistent benefits of adjunctive IA supplements) may trigger medical necessity review or denial if submitted without strong supporting clinical justification.

    • Include long‑term outcome data and justification when requesting coverage for adjunctive IA agents
    • Be prepared for investigational review for biologics with limited or mixed evidence
    Documentation Required

    Document image‑guided injection accuracy and confirmation

    Ultrasound guidance with CT confirmation achieved high intra‑articular needle placement accuracy in cited cohorts; document image‑guided technique and confirmation to support claims of accurate intra‑articular delivery.

    • Report whether CT confirmation was used and CT‑confirmed intra‑articular placement rates if available
    • Document sterile technique and any complications
    Documentation Required

    Image‑guided injection documentation required — accuracy and sterile technique

    For image‑guided TMJ injections, document needle placement accuracy, use of sterile technique, imaging guidance modality, and any complications; failure to document technique or outcomes may prompt medical necessity review or denial.

    • Include CT confirmation or other imaging evidence of intra‑articular placement when available
    • Record procedural details (needle approach, guidance used, agent/dose, sterile field) in the operative note
    Denial Risk

    Telemedicine documentation risk — remote assessment may be insufficient for complex TMD

    Telemedicine evaluations lack a physical examination component and may be insufficient for complex or severe TMD cases; claims relying solely on remote assessment could be at risk for denial if documentation does not justify remote‑only management.

    • When using telemedicine for TMD management, document why in‑person exam was not necessary or feasible
    • Provide supplemental objective data (imaging, prior in‑person exams) to support management decisions
    Note

    No explicit authorization/denial criteria in this policy history section

    This background/policy history portion does not specify explicit authorization or denial criteria; refer to the policy’s clinical sections for actionable prior authorization and documentation requirements.

    • Use the clinical criteria and documentation sections to prepare submissions; policy history contains administrative details

    Background and Evidence Summaries

    Temporomandibular disorders (TMD) encompass a range of intracapsular (e.g., disc displacement, degenerative joint disease, synovitis) and extracapsular (muscle pain/myospasm) conditions affecting the masticatory system. Management emphasizes a conservative first‑line approach — professional physical therapy, pharmacologic management, behavioral therapies, manipulation when indicated, and reversible intra‑oral appliances — with surgery reserved for intracapsular pathology confirmed on imaging and after failure of appropriate non‑surgical care.

    Evidence-based coverage considerations (background)

    Evidence summaries and implied coverage considerations

    Arthrocentesis evidence: Arthrocentesis alone effectively reduces pain and improves jaw function in TMJ osteoarthritis across multiple studies and systematic reviews; therefore arthrocentesis is a reasonable therapeutic step prior to adjunctive intra‑articular supplements.

    Derwich et al (2021) emphasized lack of added benefit from adjunctive injections in many studies.

    IA supplements (HA, PRP/PRGF, CS): Systematic reviews indicate heterogeneous results: HA superior to saline but comparable to corticosteroids or oral appliances in some studies; PRP/PRGF show slight short‑term improvements in select trials but inconsistent long‑term benefit; overall evidence quality is low, warranting cautious, case‑by‑case use with documentation.

    Fernandez Sanroman (2016), Gutierrez (2022), Manfredini (2010), and Derwich (2021) summarize inconsistent and low‑quality evidence.

    BTX‑A for myofascial pain: Randomized trials and systematic reviews report inconsistent, low‑quality evidence for BTX‑A in myofascial TMD; routine coverage is not supported without compelling documentation.

    Evidence reviews (Chen 2015; Keenan 2015; Machado 2020) found variable trial results and limited high‑quality data.

    Evidence summaries and coverage considerations

    Key evidence-based conclusions and considerations from cited systematic reviews and trials

    Manual therapy and combination therapy conclusions: High‑quality reviews indicate manual therapy provides small improvements in pain and mouth opening; combination therapies including splints provide marginal additional benefit compared with other conservative modalities, supporting their use as part of comprehensive conservative care but not demonstrating clear superiority.

    Vieira et al (2023) and Kelemen et al (2024) provide the summarized evidence.

    IA biologics comparative findings: Network meta‑analysis and RCT data (Xu et al 2023; Fernandez Sanroman 2016) show IA agents (PRP, PRF, HA) can improve pain/MMO versus placebo, with PRF showing favorable short‑term analgesia; heterogeneity in preparations and small sample sizes limit definitive recommendations.

    Use of these agents should be supported by prior conservative care, trial data, and detailed documentation when requested for coverage.

    Telemedicine and investigational biologics: Telemedicine evidence is limited (Abdul et al 2023) and may be appropriate for select patients but insufficient for complex cases; early BMAC data are promising but preliminary and investigational pending larger trials (Fayed et al 2024).

    The background sections reiterate that several treatments have limited or low‑quality evidence: intra‑articular biologics like PRGF/PRP show inconsistent benefit and limited durability in some trials, and BTX‑A trials are small and heterogenous with low overall quality. These evidence limitations underpin the policy’s cautious stance toward routine coverage of such interventions.

    Definitions and Key Terms

    inv-77: Arthrocentesis (for TMJ internal derangement)
    Procedure definitionArthrocentesis for TMJ internal derangement involves insertion of two separate single-needle portals or a single double-needle portal for input and output of fluids, including insufflation, lavage, manipulation for lysis of adhesions, and elective steroid infusion.
    IndicationsMedically necessary when imaging and clinical exam reveal anchored disc phenomenon, anterior disc displacement without reduction and without effusion, osteoarthritis without fibrosis or loose bone particles, open lock, or hemarthrosis.
    Therapeutic elementsMay include insufflation of the joint space, lavage, mandibular manipulation to lyse adhesions, and elective intra-articular steroid infusion.
    inv-78: Arthrocentesis (CPT 20605)
    CPT descriptor20605: Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular) without ultrasound guidance.
    Coding constraintsCPT 20605 is noted in the policy with specific not-covered indications (eg, not covered for viscosupplementation injection; not covered for intra-articular injections of rituximab or analgesic).
    Clinical implicationUse 20605 for TMJ arthrocentesis when no ultrasound guidance/recording is used; select alternative codes (eg, 20611) when ultrasound guidance with permanent recording is performed.
    inv-79: TMJ arthroscopy (CPT 29800, 29804)
    Diagnostic arthroscopy (29800)CPT 29800: Arthroscopy, temporomandibular joint; diagnostic, with or without synovial biopsy.
    Surgical arthroscopy (29804)CPT 29804: Arthroscopy, temporomandibular joint; surgical.
    Coding contextArthroscopy codes are listed among covered codes when selection criteria (eg, imaging-confirmed adhesions, fibrosis, degenerative joint disease) are met.
    inv-80: Intracapsular vs extracapsular TMD
    Intracapsular TMDIntracapsular abnormalities include internal derangements such as anterior disc displacement with or without reduction, disc perforation or fragmentation leading to degenerative joint disease, rheumatoid arthritis, synovitis, and neoplasia.
    Extracapsular TMDExtracapsular abnormalities consist of myalgia or myospasm related to trauma or parafunctional habits (eg, bruxism), tooth pain, or postural abnormalities.
    Clinical relevanceSurgical interventions are generally reserved for intracapsular pathology confirmed by imaging; extracapsular (muscular) TMD is managed conservatively.
    inv-81: Conservative/reversible therapy
    DefinitionConservative/reversible therapy comprises non-surgical measures that do not permanently alter anatomy, including occlusal appliance therapy, physical therapy, medical management, and cognitive-behavioral or relaxation therapies.
    Policy expectationsPrudence dictates exhausting non-surgical, conservative therapy prior to invasive therapies; such therapies are customarily tried and documented before surgery is considered.
    Appliance noteAn intra-oral splint may be medically necessary for TMD/TMJ therapy, but appliances for bruxism are typically excluded under Aetna medical plans and prolonged use beyond 6 months generally requires individual review.
    inv-82: Phototherapy
    DefinitionPhototherapy refers to low-level laser therapy (LLLT) or light-emitting diode (LED) therapy applied to masticatory muscles and the TMJ to treat muscle pain.
    Clinical research contextDosing, cumulative effects, and optimal wavelengths/sources are subjects of clinical trials; randomized placebo-controlled studies are ongoing to evaluate efficacy.
    Policy stanceEvidence for phototherapy is under investigation; larger trials are needed to establish effectiveness and standardized protocols.
    inv-83: Somatosensory testing / QST
    DefinitionSomatosensory testing / Quantitative sensory testing (QST) comprises objective sensory assessments such as tactile, pin-prick, pressure pain threshold (PPT), and pressure pain tolerance to evaluate somatosensory function in TMD patients.
    ApplicationsQST is used in trials to characterize somatosensory abnormalities, assess responses to interventions, and to calculate z-scores against reference data.
    InterpretationQST findings commonly show somatosensory gain or loss in TMD patients; results inform research and may help phenotype pain mechanisms but are not routine clinical diagnostics.
    inv-84: Somatosensory testing / CPM
    DefinitionConditioned pain modulation (CPM) testing examines pain inhibition by measuring pressure pain thresholds before, during, and after a conditioning painful stimulus (eg, cold application).
    Use in TMD assessmentCPM can be assessed at the TMJ and remote sites (eg, thenar muscle) to compare inhibitory pain mechanisms between TMD patients and healthy controls.
    Study findingsCPM effects were observed in both TMD patients and controls with no significant between-group difference in some studies, indicating heterogeneous central pain modulation in TMD.
    inv-85: Omentin-1
    DefinitionOmentin-1 is a circulating adipokine measurable by ELISA; lower plasma omentin-1 levels were associated with higher odds of chronic painful TMD after adjustment for covariates.
    Research implicationFindings suggest inflammatory pathways may mediate TMD pain and that omentin-1 may be a potential biomarker, pending further validation.
    Clinical statusCurrent evidence is exploratory and does not support routine clinical use of omentin-1 testing for TMD management.
    inv-86: TMJ osteoarthritis (TMJ OA)
    DefinitionTMJ osteoarthritis (TMJ OA) is described as a low-inflammatory, multi-factorial disorder characterized by degenerative changes of the joint and is reviewed in the context of arthrocentesis and intra-articular supplements.
    Treatment contextArthrocentesis alone has been shown to reduce pain and improve jaw function in TMJ OA; evidence for routine additional intra-articular supplements is inconsistent.
    Evidence cautionSystematic reviews recommend larger, multi-center trials to determine whether adjunctive intra-articular treatments confer added benefit over arthrocentesis alone.
    inv-87: Platelet-rich plasma (PRP)
    DefinitionPlatelet-rich plasma (PRP) is an autologous blood-derived concentrate used as an intra-articular injection for TMD/TMJ-OA.
    Evidence summaryEvidence for PRP in TMJ-OA is limited and heterogeneous; some small studies reported short-term improvements in pain and range of motion, but standardized preparation and dosing are lacking.
    Policy implicationBecause of variable and low-quality evidence, routine coverage of PRP for TMJ indications is not supported without strong clinical justification and documentation.
    inv-88: Ultrasonography (US) for TMJ
    DefinitionUltrasonography (US) for TMJ is a noninvasive, dynamic, low-cost imaging technique for evaluating internal derangement when MRI is not readily available.
    Performance characteristicsReported sensitivities and specificities vary by target: joint effusion sensitivity 0–72% and specificity 70–83% versus MRI; disc displacement sensitivity/specificity in some analyses around 75.6% and 69.1% respectively.
    Clinical roleHigh-resolution dynamic US may improve diagnostic accuracy and could complement MRI for surveillance; standardization and further research are needed.
    inv-89: Maximal incisal opening (MIO / MMO)
    DefinitionMaximal incisal opening (MIO / MMO) is a clinical measure of mouth opening (interincisal distance) used to assess functional limitation in TMJ studies.
    Outcome useMIO/MMO is reported as an outcome in trials of intra-articular injections and surgical procedures to quantify functional improvement.
    Measurement noteReported improvements in interincisal opening are commonly cited (eg, millimeter gains at 18–36 months post-procedure in prosthesis studies).
    inv-90: Facial Pain Index (FPI)
    DefinitionFacial Pain Index (FPI) = facial pain intensity × facial pain duration / 100; used as a primary endpoint in clinical trials (eg, propranolol trial).
    Trial applicationFPI was the primary endpoint in a phase IIb trial of propranolol for TMD myalgia assessing mean change from baseline to week 9 and responder thresholds (≥30% and ≥50% reductions).
    InterpretationResponder analyses (eg, proportion achieving ≥30% reduction) may show clinically meaningful benefits even when mean differences are non-significant.
    inv-91: Maximum mouth opening (MMO)
    DefinitionMaximum mouth opening (MMO) is the interincisal opening in millimeters used as a standardized clinical outcome to assess functional change in TMD studies.
    Use across trialsMMO is reported across RCTs and systematic reviews evaluating manual therapy, intra-articular injections (HA/PRP/PRF), and surgical interventions to quantify improvement in jaw opening.
    Interpretive cautionObserved MMO gains in systematic reviews and trials may be statistically significant but of small magnitude that might not always be clinically important.
    inv-92: Platelet-rich fibrin (PRF)
    DefinitionPlatelet-rich fibrin (PRF) is an autologous platelet concentrate used for intra-articular injections in TMD and in a network meta-analysis demonstrated favorable short-term analgesic and functional effects compared with PRP and HA.
    Evidence timeframePRF showed better analgesic effects at 1 and 3 months in pooled analyses, though comparative differences vary by follow-up and outcome (pain vs MMO).
    LimitationsHeterogeneity in study methods and small sample sizes limit definitive conclusions; further RCTs are needed to confirm durability of benefit.
    inv-93: Bone marrow aspirate concentrate (BMAC)
    DefinitionBone marrow aspirate concentrate (BMAC) is a biologic concentrate containing mesenchymal stem cells and growth factors used investigationally as an intra-articular injection for TMJ osteoarthritis.
    Preliminary trial contextA small pilot trial (24 patients) comparing BMAC to HA after arthrocentesis reported trends toward long-term joint repair at 12–18 months in the BMAC group, but findings are preliminary and require larger confirmatory studies.
    Policy implicationBMAC for TMJ OA is considered investigational/experimental pending larger studies and is a candidate for prior authorization with trial-level evidence if requested.

    Revision History and Administrative Dates

    1995-08-01policy_effective

    Policy originally became effective on 1995-08-01.

    2026-03-12policy_reviewLatest

    Policy last reviewed on 2026-03-12.

    Prior authorization and robust evidence recommended for experimental biologic IA injections.